Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Does the bleomycin sensitivity assay express cancer phenotype?

Gábor Székely1, Eva Remenár, Miklós Kásler

  • 1Department of Oncocytogenetics and Department of Head and Neck Surgery, National Institute of Oncology, Ráth Gy. u. 7-9, H-1122 Budapest, Hungary.

Mutagenesis
|December 11, 2002
PubMed
Summary

The bleomycin (BLM) sensitivity assay may not distinguish head and neck cancer patients from alcoholic patients, suggesting it doesn't solely predict inherited cancer susceptibility. Elevated mutagen sensitivity was observed in both groups compared to controls.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genetic identification of Árpád Dynasty members from the ossuary of the Royal Basilica at Székesfehérvár.

iScience·2026
Same author

Uncovering the Genetic Structure of the Sekler Population in Transylvania Through Genome-Wide Autosomal Data.

Genes·2026
Same author

A study of radiation workers: Dosimetry, chromosomal aberrations, and cancer risk.

Mutation research. Genetic toxicology and environmental mutagenesis·2025
Same author

Assessment of the predictive power the radiation-induced lymphocyte apoptosis method in prostate cancer patients.

Scientific reports·2025
Same author

Analysis of Gyimes Csango population samples on a high-resolution genome-wide basis.

BMC genomics·2024
Same author

Effectiveness of SARS-CoV-2 primary vaccines and boosters in patients with type 2 diabetes mellitus in Hungary (HUN-VE 4 Study).

BMJ open diabetes research & care·2024

Area of Science:

  • Genetics and Cancer Epidemiology
  • Cytogenetics and Mutagenesis

Background:

  • The bleomycin (BLM) sensitivity assay measures in vitro lymphocyte sensitivity to BLM, indicated by chromatid breaks per cell (b/c).
  • Elevated BLM sensitivity is linked to increased cancer susceptibility and has high heritability, suggesting a genetic basis.
  • Clarifying if BLM sensitivity specifically identifies cancer phenotype versus other risk factors like alcohol and tobacco is crucial.

Purpose of the Study:

  • To determine if the BLM test differentiates head and neck cancer patients (HNCPs) from alcoholic patients (ALCs) with similar environmental exposures but without cancer.
  • To investigate whether BLM sensitivity reflects inherited cancer susceptibility or is influenced by other factors.
  • To assess the utility of the BLM assay as a biomarker for cancer susceptibility.

Main Methods:

Related Experiment Videos

  • Conventional chromosome analysis and the bleomycin (BLM) assay were performed on 156 HNCPs, 51 ALCs, 146 healthy non-smokers/non-drinkers, and 149 non-drinking smokers.
  • Spontaneous chromosomal aberration (CA) rates and mutagen sensitivity (b/c) were measured.
  • Statistical analysis was used to compare CA rates and b/c values across groups.

Main Results:

  • Spontaneous CA rates were similar in HNCPs, ALCs, and healthy smokers (2.8%) but higher than controls (2.25%), indicating an association with tobacco smoking.
  • Mutagen sensitivity (b/c) was significantly elevated in both HNCPs (1.13 b/c) and ALCs (1.29 b/c) compared to controls (1.01 b/c).
  • A substantial proportion (46%) of Hungarian controls exhibited mutagen sensitivity, higher than previously reported.

Conclusions:

  • The BLM test, under the study's conditions, did not significantly differentiate HNCPs from ALCs, suggesting it may not solely characterize inherited cancer susceptibility.
  • The high prevalence of mutagen sensitivity in controls warrants further investigation.
  • The BLM assay could potentially serve as a biomarker for cancer susceptibility when spontaneous aberrant cell frequency is ≥2% and b/c is ≥1.